.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,455,499

« Back to Dashboard

Claims for Patent: 6,455,499

Title: Methods for treating disorders associated with LHRH activity
Abstract:Methods of treating a subject having a disorder associated with LHRH activity are disclosed.
Inventor(s): Roeske; Roger W. (Indianapolis, IN)
Assignee: Indiana University Foundation (Bloomington, IN)
Application Number:09/256,599
Patent Claims: 1. A method of treating a subject having a disorder associated with LHRH activity, comprising administering to a subject an effective amount of a peptide compound which inhibits LHRH activity, wherein the peptide compound comprises a structure:

wherein A is pyro-Glu, Ac-D-Nal, Ac-D-Qal, Ac-Sar, or Ac-D-Pal; B is His or 4-Cl-D-Phe; C is Trp, D-Pal, D-Nal, L-Nal-D-Pal(N--O), or D-Trp; D is Ser; E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile; F is D-Asn or D-Gln; G is Leu or Trp; H is Lys(iPr), Gln, Met, or Arg; I is Pro; and J is Gly-NH.sub.2 or D-Ala-NH.sub.2 ;

or a pharmaceutically acceptable salt thereof, thereby treating a subject having a disorder associated with LHRH activity.

2. A method of treating a subject having a disorder associated with LHRH activity, comprising administering to a subject an effective amount of a peptide compound which inhibits LHRH activity, wherein the peptide compound comprises a structure:

wherein A is pyro-Glu, Ac-D-Nal, Ac-D-Qal, Ac-Sar, or Ac-D-Pal; B is His or 4-Cl-D-Phe; C is Trp, D-Pal, D-Nal, L-Nal-D-Pal(N--O), or D-Trp; D is Ser; E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile; F is D-Asn; G is Leu or Trp; H is Lys(iPr), Gln, Met, or Arg; I is Pro; and J is Gly-NH.sub.2 or D-Ala-NH.sub.2 ;

or a pharmaceutically acceptable salt thereof, thereby treating a subject having a disorder associated with LHRH activity.

3. The method of any one of claim 1 or 2, wherein said peptide compound comprises a structure:

or a pharmaceutically acceptable salt thereof.

4. The method of any one of claim 1 or 2, wherein said peptide compound comprises a structure:

or a pharmaceutically acceptable salt thereof.

5. A method of treating a subject having a disorder associated with LHRH activity, comprising administering to a subject an effective amount of a peptide compound which inhibits LHRH activity, wherein the peptide compound comprises a structure:

wherein A is D-Glu, L-Glu, or an analogue thereof; B is D-His, L-His, or an analogue thereof; C is D-Trp, L-Trp, or an analogue thereof; D is D-Ser, L-Ser, or an analogue thereof; E is D-Tyr, L-Tyr, or an analogue thereof; F is D-asparagine, L-asparagine, D-glutamine, or L-glutamine; G is D-Leu, L-Leu or an analogue thereof; H is D-Arg, L-Arg, or an analogue thereof; I is D-Pro, L-Pro, or an analogue thereof; and J is D-Gly, L-Gly, or an analogue thereof; or a pharmaceutically acceptable salt thereof.

6. A method of treating a subject having a disorder associated with LHRH activity, comprising administering to a subject an effective amount of a peptide compound which inhibits LHRH activity, wherein the peptide compound comprises a structure:

wherein A is D-Glu, L-Glu, or an analogue thereof; B is D-His, L-His, or an analogue thereof; C is D-Trp, L-Trp, or an analogue thereof; D is D-Ser, L-Ser, or an analogue thereof; E is D-Tyr, L-Tyr, or an analogue thereof; F is D-asparagine, L-asparagine, D-glutamine, or L-glutamine; G is D-Leu, L-Leu or an analogue thereof; H is D-Arg, L-Arg, or an analogue thereof; and I is D-Pro, L-Pro, or an analogue thereof;

or a pharmaceutically acceptable salt thereof.

7. A method of treating a subject having a disorder associated with LHRH activity, comprising administering to a subject an effective amount of a peptide compound which inhibits LHRH activity, wherein the peptide compound comprises a structure:

wherein A is pyro-Glu, Ac-Nal, Ac-Qal, Ac-Sar, or Ac-Pal, or an analogue thereof; B is His or 4-Cl-Phe, or an analogue thereof; C is Trp, Pal, Nal, Nal-Pal(N--O), or Trp, or an analogue thereof; D is Ser, or an analogue thereof; E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile, or an analogue thereof; F is Asn or Gln; G is Leu or Trp, or an analogue thereof; H is Lys(iPr), Gln, Met, or Arg, or an analogue thereof; I is Pro, or an analogue thereof; and J is Gly-NH.sub.2 or Ala-NH.sub.2, or an analogue thereof;

or a pharmaceutically acceptable salt thereof.

8. The method of claim 7, wherein the peptide compound comprises the structure:

wherein A is pyro-Glu, Ac-Nal, Ac-Qal, Ac-Sar, or Ac-Pal, or an analogue thereof; B is His or 4-Cl-Phe, or an analogue thereof; C is Trp, Pal, Nal, L-Nal-Pal(N--O), or Trp, or an analogue thereof; D is Ser, or an analogue thereof; E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile, or an analogue thereof; F is Asn; G is Leu or Trp, or an analogue thereof; H is Lys(iPr), Gln, Met, or Arg, or an analogue thereof; I is Pro, or an analogue thereof; and J is Gly-NH.sub.2 or Ala-NH.sub.2, or an analogue thereof;

or a pharmaceutically acceptable salt thereof.

9. A method of treating a subject having a disorder associated with LHRH activity, comprising administering to a subject an effective amount of a peptide compound which inhibits LHRH activity, wherein the peptide compound comprises a structure:

wherein A is pyro-Glu, Ac-Nal, Ac-Qal, Ac-Sar, or Ac-Pal, or an analogue thereof; B is His or 4-Cl-Phe, or an analogue thereof; C is Trp, Pal, Nal, Nal-Pal(N--O), or Trp, or an analogue thereof; D is Ser, or an analogue thereof; E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile, or an analogue thereof; F is Asn or Gln; G is Leu or Trp, or an analogue thereof; H is Lys(iPr), Gln, Met, or Arg, or an analogue thereof; and I is Pro, or an analogue thereof;

or a pharmaceutically acceptable salt thereof.

10. The method of claim 9, wherein the peptide compound comprises the structure:

wherein A is pyro-Glu, Ac-Nal, Ac-Qal, Ac-Sar, or Ac-Pal, or an analogue thereof; B is His or 4-Cl-Phe, or an analogue thereof; C is Trp, Pal, Nal, L-Nal-Pal(N--O), or Trp, or an analogue thereof; D is Ser, or an analogue thereof; E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile, or an analogue thereof; F is Asn; G is Leu or Trp, or an analogue thereof; H is Lys(iPr), Gln, Met, or Arg, or an analogue thereof; and I is Pro, or an analogue thereof;

or a pharmaceutically acceptable salt thereof.

11. A method of treating a subject having a disorder associated with LHRH activity, comprising administering to a subject an effective amount of a peptide compound which inhibits LHRH activity, wherein the peptide compound comprises a structure:

wherein A is pyro-Glu, Ac-D-Nal, Ac-D-Qal, Ac-Sar, or Ac-D-Pal, or an analogue thereof; B is His or 4-Cl-D-Phe, or an analogue thereof; C is Trp, D-Pal, D-Nal, L-Nal-D-Pal(N--O), or D-Trp, or an analogue thereof; D is Ser, or an analogue thereof; E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile, or an analogue thereof; F is D-Asn or D-Gln; G is Leu or Trp, or an analogue thereof; H is Lys(iPr), Gln, Met, or Arg, or an analogue thereof; and I is Pro, or an analogue thereof;

or a pharmaceutically acceptable salt thereof.

12. The method of claim 11, wherein the peptide compound comprises the structure:

wherein A is pyro-Glu, Ac-D-Nal, Ac-D-Qal, Ac-Sar, or Ac-D-Pal, or an analogue thereof; B is His or 4-Cl-D-Phe, or an analogue thereof; C is Trp, D-Pal, D-Nal, L-Nal-D-Pal(N--O), or D-Trp, or an analogue thereof; D is Ser, or an analogue thereof; E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile, or an analogue thereof; F is D-Asn; G is Leu or Trp, or an analogue thereof; H is Lys(iPr), Gln, Met, or Arg, or an analogue thereof; and I is Pro, or an analogue thereof;

or a pharmaceutically acceptable salt thereof.

13. A method of treating a subject having a disorder associated with LHRH activity, comprising administering to a subject an effective amount of a peptide compound which inhibits LHRH activity, wherein the peptide compound comprises a structure:

wherein B is D-His, L-His, or an analogue thereof; C is D-Trp, L-Trp, or an analogue thereof; D is D-Ser, L-Ser, or an analogue thereof; E is D-Tyr, L-Tyr, or an analogue thereof; F is D-asparagine, L-asparagine, D-glutamine, or L-glutamine; G is D-Leu, L-Leu or an analogue thereof; H is D-Arg, L-Arg, or an analogue thereof; I is D-Pro, L-Pro, or an analogue thereof; and J is D-Gly, L-Gly, or an analogue thereof;

or a pharmaceutically acceptable salt thereof.

14. The method of any one of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein said disorder associated with LHRH activity is selected from the group consisting of precocious puberty, prostate cancer, ovarian cancer, benign prostatic hypertrophy, endometriosis, uterine fibroids, breast cancer, premenstrual syndrome, and polycystic ovary syndrome.

15. The method of any one of claim 1, 3, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein said disorder associated with LHRH activity is precocious puberty.

16. The method of any one of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein said disorder associated with LHRH activity is prostate cancer.

17. The method of any one of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein said disorder associated with LHRH activity is ovarian cancer.

18. The method of The method of any one of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein said disorder associated with LHRH activity is benign prostatic hypertrophy.

19. The method of any one of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein said disorder associated with LHRH activity is endometriosis.

20. The method of any one of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein said disorder associated with LHRH activity is uterine fibroids.

21. The method of any one of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein said disorder associated with LHRH activity is breast cancer.

22. The method of any one of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein said disorder associated with LHRH activity is premenstrual syndrome.

23. The method of any one of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein said disorder associated with LHRH activity is polycystic ovary syndrome.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc